Abstract
Rituximab plus CHOP (R-CHOP) has been proven to increase overall survival in aggressive bcl-2-positive lymphoma patients. Using competing risk analysis, we studied the long-term impact of this treatment in patients from a GELA trial: R-CHOP prevented from progression or relapse in both bcl-2-positive and bcl-2-negative patients without increasing the risk of death in complete remission.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Age Factors
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / pharmacology*
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / pharmacology
-
Disease-Free Survival
-
Doxorubicin / administration & dosage
-
Doxorubicin / pharmacology
-
Drug Resistance, Neoplasm / drug effects*
-
Female
-
Gene Expression Regulation, Neoplastic / drug effects
-
Genes, bcl-2
-
Humans
-
Immunotherapy*
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Lymphoma, Large B-Cell, Diffuse / mortality
-
Male
-
Middle Aged
-
Multicenter Studies as Topic / statistics & numerical data
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / physiology*
-
Prednisone / administration & dosage
-
Prednisone / pharmacology
-
Proportional Hazards Models
-
Proto-Oncogene Proteins c-bcl-2 / physiology*
-
Randomized Controlled Trials as Topic / statistics & numerical data
-
Risk
-
Rituximab
-
Survival Analysis
-
Vincristine / administration & dosage
-
Vincristine / pharmacology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Neoplasm Proteins
-
Proto-Oncogene Proteins c-bcl-2
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone